Læknablaðið - 15.07.2000, Side 18

r
FRÆÐiGREINAR / HJARTALÆKNINGAR
aldrei liluti af rannsókn þessari líkt og hópur karla
með meðalslæma þykknun á vinstri slegli. A sama
hátt hlýtur að vera mikilvægt að greina hin mismun-
andi stig þykknunar á vinstri slegli meðal beggja
kynja til að meta hverjir eigi að fá meðferð í framtíð-
inni og þá hvaða meðferð sé viðeigandi á hverju stigi.
Innan fárra ára má búast við niðurstöðum LIFE
rannsóknarinnar sem ber saman meðferð beta blokk-
ara og sérhæfðs angíótensín hemja í þátttakendum
með háþrýsting og þykknun á vinstri slegli. I þeirri
rannsókn er jafnframt könnuð á framskyggnan hátt
lifun þátttakenda með tilliti til lyfjameðferðar (33).
Við ályktum að algengi og nýgengi þykknunar á
vinstri slegli fari vaxandi með auknum aldri. Þykkn-
unin tengist þögulli kransæðastíflu og ST-T breyting-
um meðal karla og að forspárþáttur um uppkomu
hennar er fyrst og fremst hjartaöng en miklar reyk-
ingar virðast verndandi. Konur með þykknun á
vinstri slegli hafa mun verri horfur en samanburðar-
hópur og líkur á kransæðadauða fara vaxandi þegar
líður frá greiningu þykknunar á vinstri slegli.
Þakkir
Þökkum Elínborgu Sveinbjarnardóttur og öðru
starfsfólki Hjartaverndar fyrir aðstoð við gerð rann-
sóknarinnar og frágang greinarinnar.
Heimildir
1. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R,
Zampi I, et al. Prognostic value of a new electrocardiographic
method for diagnosis of left ventricular hypertrophy in
essential hypertension. J Am Coll Cardiol 1998; 31: 383-90.
2. Aronow WS, Kronzon I, Koenigsberg M. Congestive heart
failure, coronary events and atherothrombotic brain in elderly
blacks and whites with systemic hypertension and with and
without echocardiographic and electrocardiographic evidence
of left ventricular hypertrophy. Am J Cardiol 1991; 67: 295-9.
3. Kannel W, Gordon T, Offutt D. Left ventricular hypertrophy
by electrocardiogram. Prevalence, incidence and mortality in
the Framingham Study. Ann Intern Med 1969; 71: 89-105.
4. Agabiti Rosei E, Muiesan ML. Left ventricular hypertrophy:
how to influence an important risk factor in hypertension. J
Hypertension 1998; 16/Suppl. 1: S53-S58.
5. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am
HeartJ 1991; 121(3Ptl): 951-7.
6. DiBianco R. The changing syndrome of heart failure: an an-
notated review as we approach the 21st century. J Hyper-
tension 1994; 12/Suppl. 4: S73-S87.
7. Abraham WT, Bourge RC, Centor RM, Kasper EK. 5 million
failing hearts-reaching patients, reaching goals, 1999. Avail-
able from: http://www.medscape.com
8. Thrainsdottir IS, Hardarson Th, Thorgeirsson G, Sigvaldason
H, Sigfusson N. The epidemiology of right bundle branch
block and its association with cardiovascular morbidity-The
Reykjavik Study. Eur Heart J 1993; 14:1590-6.
9. Rose GA, Blackburn H. Cardiovascular survey methods.
Geneva: World Health Organization; 1968.
10. WHO MONICA Project. MONICA Manual, revised edition.
Geneva: Cardiovascular Diseases Unit, WHO; 1990.
11. Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N.
Prevalence of coronary heart disease in Icelandic men in 1968-
1986. The Reykjavik Study. Eur Heart J 1993; 14: 584-91.
12. Jónsdóttir LS, Sigfusson N, Sigvaldason H, Thorgeirsson G.
Incidence and prevalence of recognised and unrecognised
myocardial infarction in women. The Reykjavik Study. Eur
Heart J 1998; 19:1011-8.
13. Gebski V, Leung O, McNeil D, Linn D. SPIDA user’s manual,
version b. New South Wales, Australia: Statistical computing
laboratory, Macquarie University; 1992.
14. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular
hypertrophy in hypertensive patients. A metaanalysis of 109
treatment studies. Am J Hypertension 1992; 5: 95-110.
15. Korner PI, Jennings GL. Assessment of prevalence of left
ventricular hypertrophy in hypertension. J Hypertension 1998;
16: 715-23.
16. Schmieder RE, Schlach MP, Klingbeil AU, Martus P. Update
on reversal of left ventricular hypertrophy in essential hyper-
tension. A meta-analysis of all randomized double-blind
studies until december 1996. Nephrol Dial Transpl 1998, 13;
564-9.
17. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH.
Relation of left ventricular mass and geometry to morbidity
and mortality in uncomplicated essential hypertension. Ann
Intern Med 1991; 114: 345-52.
18. Sloan PJM, Beevers DG. Hypertension and the heart. A
review. Eur Heart J 1983,4:215-22.
19. Levy D, Anderson KM, Savage DD. Kannel WB, Christiansen
JC, Castelli WP. Echocardiographically detected left ventricu-
lar hypertrophy: Prevalence and risk factors. The Framingham
Heart Study. Ann Intern Med 1988; 108: 7-13.
20. Franz IW, íonnesmann U, Miiller JFM. Time course of com-
plete normalization of left ventricular hypertrophy during
long term antihypertensive therapy with angiotensin conver-
ting-enzyme inhibitors. Am J Hypert 1998; 11: 631-9.
21. Kannel WB. Left ventricular hypertrophy as a risk factor in
arterial hypertension. Eur Heart J 1992; 13/Suppl. D: 82-88.
22. Thorgeirsson G, Sigvaldason H, Sigfusson N. The epidemio-
logy of heart failure in Iceland. The Reykjavik Study [ab-
stract]. IX International Congress on Circumpolar Health,
Reykjavik, June 20-25,1993. Abstracts, D330.
23. Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N.
Prognostic role of cardiovascular risk factors from men with
cardiomegaly (The Reykjavik Study). Am J Cardiol 1996; 78:
1355-61.
24. Okin PM, Roman MJ, Devereux RB, Kligfield P. Gender diffe-
rences and the electrocardiogram in left ventricular hyper-
trophy. Hypertension 1995; 25: 242-9.
25. Okin PM, Roman MJ, Devereux RB, Pickering TG, Borer JS,
Kligfield P. Time voltage QRS area of the 12-lead electro-
cardiogram. Detection of left ventricular hypertrophy. Hyper-
tension 1998;31:937-42.
26. Yamashita S, Dohi Y, Miyagawa K, Kojima M, Sato K. Relia-
bility of the electrocardiogram for detecting left ventricular
hypertrophy in the elderly. Am J Cardiol 1998; 81: 650-2.
27. Casale PN, Devereux RB, Milner M, Zullo G, Harsfield GA,
Pickering TG, et al. Value of echocardiographic measurement
of left ventricular mass in predicting cardiovascular morbid
events in hypertensive men. Ann Intern Med 1986; 105:173-8.
28. Aronow WS, Schwartz KS, Koeningsberg M. Value of five
electrocardiographic criteria correlated with echocardio-
graphic left ventricular hypertrophy in elderly patients. Am J
Noninvas Cardiol 1987; 1:152-4.
29. Marcus R, Krause L, Weder AB, Dominguez-Mejia A, Schork
NJ, Julius S. Sex-specific determinants of left ventricular mass
in the Tecumseh Blood Pressure Study. Circulation 1994; 90:
928-36.
30. Aronow WS, Epstein S, Koenigsberg M, Schwartz KS.
Usefulness of echocardiographic left ventricular hypertrophy,
ventricular tachycardia and complex ventricular arrhythmias
in predicting ventricular fibrillation or sudden cardiac death in
elderly patients. Am J Cardiol 1988; 62:124-5.
31. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH.
Relation of left ventricular mass and geometry to morbidity
and mortality in uncomplicated essential hypertension. Ann
Intern Med 1991; 114:345-52.
32. Ho KKL, Dinsky JL, Kannel WB, Levy D. The epidemiology
of heart failure. The Framingham Study. J Am Coll Cardiol
1993; 22/Suppl. A: 6A-13A.
33. Dahlöf B, Devereux RB, Kjeldsen JS, Beevers G, de Faire U,
Fyhrquist F, et al. Characteristics of 9194 patients with left
ventricular hypertrophy: the LIFE study. Losartan interven-
tion for endpoint reduction in hypertension. Hypertension,
1998; 32:989-97.
494 Læknablaðið 2000/86